Lupus Nephritis

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

Twelve years is a long time by most measures, but in a field has rapidly changing as lupus nephritis research, it may as well be an eternity.

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in Lupus Science & Medicine.

Tacrolimus appears to have “synergistic” interactions with mycophenolate mofetil and cyclophosphamide for the treatment of renal involvement in systemic lupus erythematosus, according to observational data published in BMC Rheumatology.

WASHINGTON — Early triple therapy may be the most effective strategy for lupus nephritis, according to the new 2024 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis.

SAN DIEGO — Help with transportation, copays and treatment adherence were the top three needs affecting health care according to a group of patients participating in a lupus navigator pilot program.

Early treatment with mycophenolate mofetil can reduce subsequent risks for severe flares and lupus nephritis in newly diagnosed systemic lupus erythematosus, according to data published in JAMA Network Open.

Repeat kidney biopsies may help patients with lupus nephritis manage disease flares, particularly those who transition between proliferative and non-proliferative disease classes, data from a racially diverse study cohort show.

Kezar Life Sciences has paused a phase 2b trial of zetomipzomib in active lupus nephritis after reporting four patient deaths, according to a press release from the manufacturer.

The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.